In 2014, MAPS spun out a individual division to direct study and put together for an eventual FDA application, which it submitted at the conclusion of last yr. In early 2024, that offshoot was renamed Lykos Therapeutics.In 1938, as the now acquainted story goes, the Swiss chemist Albert Hofmann was Operating for the Sandoz Company, a pharmaceutical